TNFRSF17 and Miyoshi myopathy: In addition, particular key proteins viable for the development of therapeutic strategies against MM, including CD38, SLAMF7, BCMA and CD138, are present on the surface of healthy and malignant PCs, though mostly up regulated in the latter population (1, 33).